BMP-6 Inhibitors
BMP-6 inhibitors constitute a diverse class of compounds designed to modulate the BMP-6 signaling pathway, influencing cellular responses governed by this specific bone morphogenetic protein. Direct inhibitors, such as DMH1, LDN-193189, and LDN-212854, target BMP type I and type II receptors, preventing their activation and disrupting downstream signaling events initiated by BMP-6. These compounds act by specifically interfering with the initiation of the BMP-6 pathway, providing precise tools for investigating the role of BMP-6 in various cellular processes. Additionally, indirect inhibitors like Dorsomorphin, SB431542, and ITD-1 modulate BMP-6 signaling through the crosstalk with the TGF-β pathway. By targeting TGF-β type I receptor (ALK5) kinase activity, these compounds disrupt shared downstream events between TGF-β and BMP-6, providing an indirect means to inhibit BMP-6-mediated cellular responses. Galunisertib and GW788388 further contribute to this indirect modulation, influencing BMP-6 signaling through ALK5 inhibition.
These diverse BMP-6 inhibitors offer valuable tools for dissecting the intricate signaling pathways and cellular responses associated with BMP-6. Researchers can selectively manipulate BMP-6 activity in a controlled manner, shedding light on the molecular mechanisms underlying its role in development, homeostasis, and potential implications in pathological conditions. The precise targeting of BMP-6 signaling at various levels enables nuanced investigations into its functions within complex cellular networks.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $209.00 $312.00 $620.00 $1026.00 | 2 | |
DMH1 is a selective BMP type I receptor inhibitor that directly targets the BMP signaling pathway. By binding to the kinase domain of BMP receptors, DMH1 prevents their activation, thereby inhibiting BMP-6 signaling. This compound specifically interferes with the initiation of the BMP-6 pathway, impeding downstream events involved in cellular responses mediated by BMP-6. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Dorsomorphin, also known as BML-275, is an AMP-activated protein kinase (AMPK) inhibitor that indirectly influences BMP-6. By inhibiting AMPK, it disrupts cellular energy homeostasis, leading to modulation of BMP-6 signaling. Dorsomorphin's impact on BMP-6 is mediated through the indirect regulation of intracellular energy status, affecting the BMP-6 pathway and downstream cellular responses. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β type I receptor, ALK5, indirectly influencing BMP-6 signaling. By targeting ALK5, it modulates the crosstalk between TGF-β and BMP pathways, impacting BMP-6 indirectly. SB431542 disrupts downstream events shared by TGF-β and BMP-6, providing an indirect means to inhibit BMP-6-mediated cellular responses. | ||||||
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | 1432597-26-6 | sc-476318 | 5 mg | $380.00 | ||
LDN-212854 is a potent and selective BMP receptor kinase inhibitor, directly affecting BMP-6 signaling. Through the inhibition of BMP receptor activity, LDN-212854 disrupts the initiation of BMP-6 pathway signaling, leading to modulation of downstream events involved in cellular responses mediated by BMP-6. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117 is a BMP type I receptor kinase inhibitor, directly impacting BMP-6 signaling. By selectively targeting BMP receptor kinases, LDN-214117 interferes with the activation of BMP-6 receptors, inhibiting downstream signaling events. This compound specifically disrupts the BMP-6 pathway, modulating cellular responses governed by BMP-6. | ||||||
ITD 1 | 1099644-42-4 | sc-507349 | 10 mg | $220.00 | ||
ITD-1 is an inhibitor of TGF-β type I receptor (ALK5) kinase activity, indirectly affecting BMP-6 signaling. By modulating ALK5 activity, ITD-1 disrupts the crosstalk between TGF-β and BMP pathways, influencing BMP-6 indirectly. ITD-1 provides an indirect means to inhibit BMP-6-mediated cellular responses by interfering with shared downstream events between TGF-β and BMP-6 signaling. | ||||||
IN-1130 | 868612-83-3 | sc-507462 | 25 mg | $435.00 | ||
IN-1130 is a BMP type I receptor kinase inhibitor, directly impacting BMP-6 signaling. By selectively targeting BMP receptor kinases, IN-1130 interferes with the activation of BMP-6 receptors, inhibiting downstream signaling events. This compound specifically disrupts the BMP-6 pathway, modulating cellular responses governed by BMP-6. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
Galunisertib (LY2157299) is a TGF-β receptor type I (ALK5) inhibitor, indirectly influencing BMP-6 signaling. By inhibiting ALK5, it modulates the crosstalk between TGF-β and BMP pathways, impacting BMP-6 indirectly. Galunisertib disrupts downstream events shared by TGF-β and BMP-6, providing an indirect means to inhibit BMP-6-mediated cellular responses. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
GW788388 is a selective inhibitor of TGF-β type I receptor (ALK5) kinase activity, indirectly affecting BMP-6 signaling. By modulating ALK5 activity, GW788388 disrupts the crosstalk between TGF-β and BMP pathways, influencing BMP-6 indirectly. GW788388 provides an indirect means to inhibit BMP-6-mediated cellular responses by interfering with shared downstream events between TGF-β and BMP-6 signaling. | ||||||